Publications

Review select publications related to our three translational research projects and the Biospecimen and Pathology Core.

Project 1: Developing a Diagnostic Test and Therapeutic Agents for Fibrolamellar Hepatocellular Carcinoma

2024

Increased protein kinase A activity induces fibrolamellar hepatocellular carcinoma features independent of DNAJB1

Liver cancer multiomics reveals diverse protein kinase A disruptions convergently produce fibrolamellar hepatocellular carcinoma

GalNAc-conjugated siRNA targeting the DNAJB1-PRKACA fusion junction in fibrolamellar hepatocellular carcinoma

Targeted degradation of protein kinase A via a stapled peptide PROTAC

2023

Disruption of proteome by an oncogenic fusion kinase alters metabolism in fibrolamellar hepatocellular carcinoma

Oncogenic addiction of Fibrolamellar hepatocellular carcinoma to the fusion kinase DNAJB1-PRKACA

Alternative lengthening of telomeres in primary hepatic neoplasms

Unique morphologic findings in the liver after stereotactic radiation for cholangiocarcinoma

2022

Clinical and demographic predictors of survival for fibrolamellar carcinoma patients-A patient community, registry-based study

Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors

Targeting BCL-XL in fibrolamellar hepatocellular carcinoma

Human liver organoids for disease modeling of fibrolamellar carcinoma

Project 2: Therapeutic Inhibition of Fibroblast Growth Factor and YAP Signaling in Cholangiocarcinoma

2024

YAP-TEAD inhibition is associated with upregulation of an androgen receptor mediated transcription program providing therapeutic escape

Metabolome-wide association identifies altered metabolites and metabolic pathways in the serum of patients with cholangiocarcinoma

Syngeneic murine models with distinct immune microenvironments represent subsets of human intrahepatic cholangiocarcinoma

2023

LCK inhibtion downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinoma

2022

Cell-free tumor DNA dominant clone allele frequency is associated with poor outcomes in advanced biliary cancers treated with platinum-based chemotherapy

Project 3: Development of a New Viral Immunotherapeutic Approach for Hepatocellular Carcinoma

2025

T cell exhaustion in poorly immunogenic HCC is partially rescued by checkpoint blockade but suppressed by oncolytic virotherapy

2023

Trap and ambush therapy using sequential primary and tumor escape-selective oncolytic viruses

Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers

2022

Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice

PD-L1 promotes myofibroblastic activation of hepatic stellate cells by distinct mechanisms selective for TGF-β receptor I versus II

Biostatistics and Bioinformatics Core

2022

Morphological heterogeneity in beta-catenin-mutated hepatocellular carcinomas: Implications for tumor molecular classification

Biospecimen and Pathology Core

2024

Genome-wide DNA methylation markers associated with metabolic liver cancer

Combined antitumor effect of the serine protease urokinase inhibitor upamostat and the sphingosine kinase 2 inhibitor opaganib on cholangiocarcinoma patient-derived xenografts

Genome-wide association study identifies high-impact susceptibility loci for HCC in North America

2023

CS-iCCA, a new clinically based staging system for intrahepatic cholangiocarcinoma: Establishment and external validation

Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma

Multitrait genome-wide analyses identify new susceptibility loci and candidate drugs to primary sclerosing cholangitis

Premature aging and reduced cancer incidence associated with near-complete body-wide Myc inactivation

2022

Aspirin, statins, non-aspirin NSAIDs, metformin, and the risk of biliary cancer: A Swedish population-based cohort study

Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes

Hepatic adenomas in patients 60 and older are enriched for HNF1A inactivation and malignant transformation

Two distinct stem cell-like subtypes of hepatocellular carcinoma with clinical significance and their therapeutic potentials

Developmental Research Program and Career Enhancement Program

2025

CLO25-087: Low serum pseudocholinesterase level predicts HCC mortality as accurately as the ALBI or MESIAH score

Role of long chain Acyl-CoA synthetases in MASH-driven hepatocellular carcinoma and ferroptosis

Utility of methylated DNA markers for the diagnosis of malignant biliary strictures

2024

PTEN deficiency induces an extrahepatic cholangitis-cholangiocarcinoma continuum via aurora kinase A in mice

2023

Cholangiocarcinoma — novel biological insights and therapeutic strategies

Immunobiology of cholangiocarcinoma

Metabolic liver cancer: associations of rare and common germline variants in one-carbon metabolism and DNA methylation genes

Metabolic reprogramming and its clinical implication for liver cancer

2022

Emerging immunotherapy for HCC: A guide for hepatologists

Fuel groundbreaking medical research!

Your donation powers the future of medicine and helps save lives.